Glomerulonephritis
Glomerulonephritis and glomerular disease guidelines — IgA nephropathy, lupus nephritis, FSGS, vasculitis, and the latest trial evidence, curated by ASNRT.
Browse all news
Explore the full ASNRT newsroom for society announcements, KDIGO guideline updates, AJNT issue releases, and notable developments across the breadth of nephrology.
Latest in this topic
The most recent evidence summaries curated by ASNRT on this topic:
ACR EULAR 2025 lupus nephritis clinical practice guidelines · Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial. · Approved therapies in the IgA nephropathy armamentarium: a summary of the evidence. · A prospective multicenter randomized controlled trial pre-emptive increase in immunosuppression for asymptomatic serological reactivation in patients with lupus nephritis in clinical remission. · TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198. · Phase 2 Apecotrep Delivers 40% Proteinuria Reduction in FSGS · Combined Anti-CD20/Anti-CD38 Therapy in Posttransplant Focal Segmental Glomerulosclerosis Recurrence: A Retrospective, International, Multicenter Study · SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis · FDA Extends Sparsentan (Filspari) sNDA Review for Focal Segmental Glomerulosclerosis · FDA Grants Priority Review of Biologics License Application for Atacicept in IgA Nephropathy · Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial · Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy. · Prospective Cohort Study of Obinutuzumab in Rituximab-Resistant Primary Membranous Nephropathy · Podocytopathies. · Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN · Successful autologous CD19 CAR T cell therapy following severe lupus flare during immunosuppressive washout in refractory lupus nephritis. · The personalized approach to rituximab treatment in membranous nephropathy: a multi-center randomized controlled trial · "A Change Is Gonna Come" to Treatment of Lupus Nephritis: A Review · Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial · C3 glomerulopathy: advancements in diagnostics and therapeutics. · A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy · [KDIGO-Update: Treatment of ANCA vasculitis]. · Bicistronic-CD19/22 Chimeric Antigen Receptor T-Cell Therapy for Childhood Refractory Lupus Nephritis. · KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). · KDIGO 2025 Clinical Practice Guideline for the Management of IgA Nephropathy and IgA Vasculitis · Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). · Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study · [Efficacy of Telitacicept combined with low-dose mycophenolate mofetil in the treatment of moderate-to-severe systemic lupus erythematosus]. · 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. · CARI Guidelines Commentary on the KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases. · Randomized Controlled Trial on the Efficacy of Reduced-Dose Cyclical Corticosteroids and Cyclophosphamide in Primary Membranous Nephropathy. · Childhood-Onset Lupus Nephritis: Unique Aspects and Challenges in Management · BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis. · Anti-CD19 chimeric antigen receptor T-cell therapy in a highly sensitized patient with focal and segmental glomerulosclerosis. · Systematic Review and Network Meta-Analysis of Initial Treatments for Lupus Nephritis · Obesity-Related Glomerulosclerosis-How Adiposity Damages the Kidneys. · Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy. · Efficacy and safety of agents for IgA nephropathy: a network meta-analysis of randomized controlled trials. · Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy · Advances in the treatment of ANCA-associated vasculitis